Lipopolysaccharide accelerates collagen-induced arthritis in association with rapid and continuous production of inflammatory mediators and anti-type II collagen antibody

Microbiology and Immunology

Volumn 57, Issue 6, 2013, Pages 445-454

  Tanaka, Shinji ^a   Toki, Tadashi ^b   Akimoto, Toshihiko ^c   Morishita, Kaoru ^c  

^a Frontier Research Laboratories   (Japan)

^b Oncology Research Laboratories   (Japan)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

Anti type II collagen antibody; Collagen induced arthritis; Inflammatory mediators; Lipopolysaccharide

Indexed keywords

AUTOANTIBODY; COLLAGEN ANTIBODY; COLLAGEN TYPE 2; COLLAGEN TYPE 2 ANTIBODY; GELATINASE B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 2; MESSENGER RNA; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTHRITIS; ARTICLE; BONE DESTRUCTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; EDEMA; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; MOLECULAR DYNAMICS; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OSTEOCLAST; PATHOGENESIS; SYNOVIOCYTE; UPREGULATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; CHEMOKINE CXCL2; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOCYTOCHEMISTRY; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MICE; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MUS;

EID: 84879347900     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/1348-0421.12052     Document Type: Article

References (49)

1. Firestein G.S. (2003) Evolving concepts of rheumatoid arthritis. Nature 423: 356-61.
2. Nandakumar K.S., Holmdahl R. (2006) Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther 8: 223.
3. Brown K.D., Claudio E., Siebenlist U. (2008) The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 10: 212.
4. Godessart N., Kunkel S.L. (2001) Chemokines in autoimmune disease. Curr Opin Immunol 13: 670-5.
5. Goldring M.B., Marcu K.B. (2009) Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther 11: 224.
6. Goldring S.R. (2002) Bone and joint destruction in rheumatoid arthritis: what is really happening? J Rheumatol Suppl 65: 44-8.
7. Ziolkowska M., Koc A., Luszczykiewicz G., Ksiezopolska-Pietrzak K., Klimczak E., Chwalinska-Sadowska H., Maslinski W. (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164: 2832-8.
8. Troughton P.R., Platt R., Bird H., El-Manzalawi E., Bassiouni M., Wright V. (1996) Synovial fluid interleukin-8 and neutrophil function in rheumatoid arthritis and seronegative polyarthritis. Br J Rheumatol 35: 1244-51.
9. Kraan M.C., Patel D.D., Haringman J.J., Smith M.D., Weedon H., Ahern M.J., Breedveld F.C., Tak P.P. (2001) The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Res 3: 65-71.
10. Yoshihara Y., Nakamura H., Obata K., Yamada H., Hayakawa T., Fujikawa K., Okada Y. (2000) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59: 455-61.
11. Tchetverikov I., Ronday H.K., Van El B., Kiers G.H., Verzijl N., Tekoppele J.M., Huizinga T.W., Degroot J., Hanemaaijer R. (2004) MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 63: 881-3.
12. Tetta C., Camussi G., Modena V., Di Vittorio C., Baglioni C. (1990) Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 49: 665-7.
13. Houssiau F.A., Devogelaer J.P., Van Damme J., De Deuxchaisnes C.N., Van Snick J. (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31: 784-8.
14. Eastgate J.A., Symons J.A., Wood N.C., Grinlinton F.M., Di Giovine F.S., Duff G.W. (1988) Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 2: 706-9.
15. Taylor P.C., Feldmann M. (2009) Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5: 578-82.
16. Williams R.O. (2007) Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. Methods Mol Biol 361: 265-84.
17. Cho Y.G., Cho M.L., Min S.Y., Kim H.Y. (2007) Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev 7: 65-70.
18. Holmdahl R., Andersson M., Goldschmidt T.J., Gustafsson K., Jansson L., Mo J.A. (1990) Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol Rev 118: 193-232.
19. Terato K., Hasty K.A., Reife R.A., Cremer M.A., Kang A.H., Stuart J.M. (1992) Induction of arthritis with monoclonal antibodies to collagen. J Immunol 148: 2103-8.
20. Williams R.O., Feldmann M., Maini R.N. (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89: 9784-8.
21. Williams R.O., Marinova-Mutafchieva L., Feldmann M., Maini R.N. (2000) Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. J Immunol 165: 7240-5.
22. Takagi N., Mihara M., Moriya Y., Nishimoto N., Yoshizaki K., Kishimoto T., Takeda Y., Ohsugi Y. (1998) Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 41: 2117-21.
23. Caccese R.G., Zimmerman J.L., Carlson R.P. (1992) Bacterial lipopolysaccharide potentiates type II collagen-induced arthritis in mice. Mediators Inflamm 1: 273-9.
24. Terato K., Harper D.S., Griffiths M.M., Hasty D.L., Ye X.J., Cremer M.A., Seyer J.M. (1995) Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 22: 137-47.
25. Terato K., Ye X.J., Miyahara H., Cremer M.A., Griffiths M.M. (1996) Induction by chronic autoimmune arthritis in DBA/1 mice by oral administration of type II collagen and Escherichia coli lipopolysaccharide. Br J Rheumatol 35: 828-38.
26. Takahashi K., Kato Y., Sugiyama T., Koide N., Kawai M., Fukada M., Yoshida T., Yokochi T. (1999) Production of murine collagen-induced arthritis using Klebsiella pneumoniae O3 lipopolysaccharide as a potent immunological adjuvant. Microbiol Immunol 43: 795-801.
27. Yoshino S., Sasatomi E., Mori Y., Sagai M. (1999) Oral administration of lipopolysaccharide exacerbates collagen-induced arthritis in mice. J Immunol 163: 3417-22.
28. Yoshino S., Ohsawa M. (2000) The role of lipopolysaccharide injected systemically in the reactivation of collagen-induced arthritis in mice. Br J Pharmacol 129: 1309-14.
29. Thornton S., Duwel L.E., Boivin G.P., Ma Y., Hirsch R. (1999) Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum 42: 1109-18.
30. Joosten L.A., Helsen M.M., Van De Loo F.A., Van Den Berg W.B. (1996) Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 39: 797-809.
31. Raychaudhuri A., Chou M., Weetall M., Jeng A.Y. (2003) Blockade of integrin VLA-4 prevents inflammation and matrix metalloproteinase expression in a murine model of accelerated collagen-induced arthritis. Inflammation 27: 107-13.
32. Miossec P., Kolls J.K. (2012) Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Dis 11: 763-76.
33. Wright H.L., Moots R.J., Bucknall R.C., Edwards S.W. (2010) Neutrophil function in inflammation and inflammatory diseases. Rheumatology (Oxford) 49: 1618-31.
34. Cascao R., Rosario H.S., Souto-Carneiro M.M., Fonseca J.E. (2010) Neutrophils in rheumatoid arthritis: more than simple final effectors. Autoimmun Rev 9: 531-5.
35. Dominical V.M., Bertolo M.B., Almeida C.B., Garrido V.T., Miguel L.I., Costa F.F., Conran N. (2011) Neutrophils of rheumatoid arthritis patients on anti-TNF-alpha therapy and in disease remission present reduced adhesive functions in association with decreased circulating neutrophil-attractant chemokine levels. Scand J Immunol 73: 309-18.
36. Tanaka D., Kagari T., Doi H., Shimozato T. (2006) Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology 119: 195-202.
37. Wipke B.T., Allen P.M. (2001) Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol 167: 1601-8.
38. Dziarski R. (1982) Preferential induction of autoantibody secretion in polyclonal activation by peptidoglycan and lipopolysaccharide. I. In vitro studies. J Immunol 128: 1018-25.
39. Dziarski R. (1982) Preferential induction of autoantibody secretion in polyclonal activation by peptidoglycan and lipopolysaccharide. II. In vivo studies. J Immunol 128: 1026-30.
40. Piguet P.F., Grau G.E., Vesin C., Loetscher H., Gentz R., Lesslauer W. (1992) Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77: 510-4.
41. Wooley P.H., Dutcher J., Widmer M.B., Gillis S. (1993) Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 151: 6602-7.
42. Cooper W.O., Fava R.A., Gates C.A., Cremer M.A., Townes A.S. (1992) Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 89: 244-50.
43. Getts M.T., Miller S.D. (2010) 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: triggering of autoimmune diseases by infections. Clin Exp Immunol 160: 15-21.
44. Leirisalo-Repo M. (2005) Early arthritis and infection. Curr Opin Rheumatol 17: 433-9.
45. Carty S.M., Snowden N., Silman A.J. (2003) Should infection still be considered as the most likely triggering factor for rheumatoid arthritis? J Rheumatol 30: 425-9.
46. Aoki S., Yoshikawa K., Yokoyama T., Nonogaki T., Iwasaki S., Mitsui T., Niwa S. (1996) Role of enteric bacteria in the pathogenesis of rheumatoid arthritis: evidence for antibodies to enterobacterial common antigens in rheumatoid sera and synovial fluids. Ann Rheum Dis 55: 363-9.
47. Heumann D., Bas S., Gallay P., Le Roy D., Barras C., Mensi N., Glauser M.P., Vischer T. (1995) Lipopolysaccharide binding protein as a marker of inflammation in synovial fluid of patients with arthritis: correlation with interleukin 6 and C-reactive protein. J Rheumatol 22: 1224-9.
48. Van Den Berg W.B., Van Lent P.L., Joosten L.A., Abdollahi-Roodsaz S., Koenders M.I. (2007) Amplifying elements of arthritis and joint destruction. Ann Rheum Dis 66 (Suppl 3): iii45-8.
49. O'neill L.A., Bryant C.E., Doyle S.L. (2009) Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 61: 177-97.